LILRB2 and cutaneous melanoma: Focusing on immune checkpoints, we found higher expression for PD-1, PD-L1, CTLA-4, IDO1, LAG3, HAVCR2, TIGIT and ILT4, as well as for CD8 in skin melanomas against the normal samples, reflecting the immunosuppressive TME in these tumors.